Shibata Kenta, Akagi Yuuki, Nozawa Naofumi, Shimomura Hitoshi, Aoyama Takao
Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510 Japan.
Department of Pharmacy, Koshigaya Municipal Hospital, 10-47-1 Higashi-Koshigaya, Koshigaya, Saitama 343-0023 Japan.
J Pharm Health Care Sci. 2017 Mar 9;3:9. doi: 10.1186/s40780-017-0078-7. eCollection 2017.
Low-dose aspirin irreversibly inhibits platelet cyclooxygenase-1 (COX-1) and suppresses platelet aggregation. It is effective for secondary prevention of cardiovascular events. Because nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly bind with COX-1, the antiplatelet effects of aspirin may be suppressed when NSAIDs are co-administered. This interaction could be avoided by avoiding simultaneous administration; however, the minimum interval that should separate the administration of aspirin and loxoprofen is not well known. In this study, we investigated how to avoid the influence of NSAIDs on the antiplatelet effects of aspirin. An in vitro experiment was performed to investigate the influence of ibuprofen and loxoprofen at various concentrations on aspirin's antiplatelet action.
Platelet aggregation and thromboxane B (TXB) levels were measured after addition of aspirin only and NSAIDs plus aspirin to platelet-rich plasma. NSAIDs were used at their maximum plasma concentrations, the assumed concentration after 6 h (for loxoprofen only), and the assumed concentration after 12 h of taking one clinical dose. Platelet aggregation threshold index (PATI), defined as the putative stimulus concentration giving 50% aggregation, was calculated as an index of aggregation activity.
PATI decreased in ibuprofen plus aspirin group compared to that in the aspirin only group, regardless of ibuprofen concentration. Furthermore, PATI significantly decreased when aspirin was added after loxoprofen--OH addition at the maximum concentration (4.1 ± 0.1 μg/mL), compared to that in aspirin only group (5.9 ± 0.1 μg/mL). PATI showed no significant difference after addition of loxoprofen at the assumed concentration after 6 h (aspirin only group, 5.0 ± 0.5 μg/mL; loxoprofen--OH plus aspirin group, 4.9 ± 0.4 μg/mL).In addition, TXB concentration tended to decrease with increasing PATI.
It is desirable to avoid ibuprofen co-administration with the usual once-daily low-dose aspirin therapy; however, a 6-h interval between loxoprofen and aspirin could avoid this potential interaction when loxoprofen is taken before aspirin.
低剂量阿司匹林可不可逆地抑制血小板环氧化酶-1(COX-1)并抑制血小板聚集。它对心血管事件的二级预防有效。由于非甾体抗炎药(NSAIDs)与COX-1可逆性结合,当NSAIDs与阿司匹林联合使用时,阿司匹林的抗血小板作用可能会受到抑制。这种相互作用可以通过避免同时给药来避免;然而,阿司匹林和洛索洛芬给药应间隔的最短时间尚不清楚。在本研究中,我们研究了如何避免NSAIDs对阿司匹林抗血小板作用的影响。进行了一项体外实验,以研究不同浓度的布洛芬和洛索洛芬对阿司匹林抗血小板作用的影响。
在富含血小板的血浆中分别加入仅阿司匹林以及NSAIDs加阿司匹林后,测量血小板聚集和血栓素B(TXB)水平。NSAIDs使用其最大血浆浓度、6小时后的假定浓度(仅针对洛索洛芬)以及服用一个临床剂量12小时后的假定浓度。计算血小板聚集阈值指数(PATI),定义为产生50%聚集的假定刺激浓度,作为聚集活性的指标。
与仅使用阿司匹林的组相比,布洛芬加阿司匹林组的PATI降低,与布洛芬浓度无关。此外,在最大浓度(4.1±0.1μg/mL)的洛索洛芬-OH添加后再添加阿司匹林时,PATI显著降低,与仅使用阿司匹林的组(5.9±0.1μg/mL)相比。在6小时后的假定浓度下添加洛索洛芬后,PATI无显著差异(仅阿司匹林组,5.0±0.5μg/mL;洛索洛芬-OH加阿司匹林组,4.9±0.4μg/mL)。此外,TXB浓度倾向于随着PATI的增加而降低。
应避免布洛芬与通常每日一次的低剂量阿司匹林疗法联合使用;然而,当在阿司匹林之前服用洛索洛芬时,洛索洛芬和阿司匹林之间间隔6小时可避免这种潜在的相互作用。